Compare clinical efficacy and safety of neoadjuvant therapy and neoadjuvant chemoradiotherapy for locally advanced rectal cancer: Meta-analysis

Table 1 General characteristics of included studies

Ref.	Country	Study type	Cases	Sample size		Inclusion in research quality evaluation
				TNT	nCRT
Garcia-Aguilar et al[9], 2015	America	Prospective study	259	199	60	6
Zhai et al[11], 2020	China	Retrospective study	134	79	55	6
Cercek et al[12], 2018	America	Retrospective study	628	308	320	8
Markovina et al[13], 2017	America	Prospective study	138	69	69	6
Zhu et al[14], 2019	America	Retrospective study	1079	372	707	8
Fernandez-Martos et al[15], 2015	America	Randomized controlled study	103	54	49	7
Maréchal et al[18], 2012	Belgium	Randomized controlled study	57	28	29	8
Calvo et al[19], 2014	Spain	Retrospective study	335	207	128	7
Bhatti et al[20], 2015	Pakistan	Retrospective study	154	93	61	7
Bujko et al[21], 2016	Poland	Randomized controlled study	515	261	254	8
Kim et al[22], 2018	South Korea	Randomized controlled study	110	54	56	7
Liang et al[23], 2019	China	Prospective study	156	76	80	5
Moore et al[24], 2017	Australia	Randomized controlled study	49	25	24	8
Wu et al[25], 2022	China	Randomized controlled study	80	40	40	8

TNT: Total neoadjuvant therapy; nCRT: Neoadjuvant chemoradiotherapy.

Table 2 Radiochemotherapy regimens and specific doses for total neoadjuvant therapy and neoadjuvant chemoradiotherapy groups

Ref.	TNT			nCRT
	IT/CT	Chemotherapy	Dose	Radiation therapy	Synchronous chemotherapy
Garcia-Aguilar et al[9], 2015	CT	mFOFLOX	5-FU 400 mg/m²; LV 200 mg/m²; OX 85 mg/m2	45.0 Gy/25 f	5-FU 225 mg/m2
Zhai et al[11], 2020	CT	CAPEOX	CAP 1000 mg/m²; OX 130 mg/m2	50.4 Gy/28f	CAP 850 mg/m²
Cercek et al[12], 2018	IT	mFOFLOX	5-FU 400 mg/m²; LV 200 mg/m²; OX 85 mg/m²	45.0 Gy/25 f	5-FU 225 mg/m²/CAP 850 mg/m²
Markovina et al[13], 2017	IT	mFOFLOX FOFLOX	5-FU/LV/OX	45.0 Gy/25 f, 45.0 Gy/25 f	5-FU/CAP
Zhu et al[14], 2019	IT	CAPEOX		50.4 Gy/25-28 f
Fernandez-Martos et al[15], 2015	IT	CAPEOX	CAP/OX	45.0 Gy/25 f	CAP
Maréchal et al[18], 2012	IT	mFOFLOX	5-FU 400 mg/m²; LV 400 mg/m²; OX 100 mg/m²	45.0 Gy/25 f	5-FU 225 mg/m²
Calvo et al[19], 2014	IT	mFOFLOX	5-FU 400 mg/m²; LV 200 mg/m²; OX 85 mg/m2	45.0 Gy/25 f	5-FU 425 mg/m2
Bhatti et al[20], 2015	IT	CAPEOX	CAP 1000 mg/m²; OX 130 mg/m²	50.4 Gy/25-28 f	CAP 825 mg/m²
Bujko et al[21], 2016	CT	mFOFLOX	5-FU/LV/OX	50.4 Gy/25-28 f	5-FU 325 mg/m²/LV 20 mg/m²
Kim et al[22], 2018	CT	CAPEOX, CAPEOX	CAP 1700 mg/m²; OX 100 mg/m²	50.4 Gy/25-28 f	CAP
Liang et al[23], 2019	CT	FOFLOX	CAP 1000 mg/m²; OX 130 mg/m²; 5-FU 400 mg/m²; LV 400 mg/m²; OX 85 mg/m2	50.4 Gy/25-28 f	CAP 825 mg/m²
Moore et al[24], 2017	CT	5-FU/LV	5-FU 450 mg/m²; LV 50 mg/m2	45.0 Gy/25 f	5-FU 225 mg/m²
Wu et al[25], 2022	CT	FOFLOX	5-FU 400 mg/m²; LV200 mg/m²; OX 85 mg/m²	50.4 Gy/25-28 f	5-FU 225 mg/m2

IT: Immunotherapy; CT: Chemotherapy; TNT: Total neoadjuvant therapy; nCRT: Neoadjuvant chemoradiotherapy; 5-FU: 5-fluorouracil; CAPEOX: Capecitabine; CAP: Community-acquired pneumonia; OX: Oxaliplatin; LV: Leucovorin; FOFLOX: Fluorouracil, oxaliplatin, leucovorin; mFOFLOX: Modified fluorouracil, oxaliplatin, leucovorin.